Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Wolf, A. M.
Right arrow Articles by Cook, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Wolf, A. M.
Right arrow Articles by Cook, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, Vol 76, Issue 5 624-628, Copyright © 1996 by The Board of Management and Trustees of the British Journal of Anaesthesia

CLINICAL INVESTIGATIONS

Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation

A. M. De Wolf, J. A. Freeman, V. L. Scott, W. Tullock, D. A. Smith, D. F. Kisor, S. Kerls and D. R. Cook
Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Clinical Pharmacokinetics/Dynamics, Glaxo Wellcome, Research Triangle Park, NC, USA; Division of Pharmacokinetics and Drug Metabolism, Glaxo Wellcome, Research Triangle Park, NC, USA; Department of Clinical Neurosciences, Glaxo Wellcome, Research Triangle Park, NC, USA

We determined the pharmacokinetics and pharmacodynamics of cisatracurium, one of the 10 isomers of atracurium, in 14 patients with end-stage liver disease undergoing liver transplantation and in 11 control patients with normal hepatic and renal function undergoing elective surgery. Blood samples were collected for 8 h after i.v. bolus administration of cisatracurium 0.1 mg kg-1 (2 x ED95). Plasma concentrations of cisatracurium and its metabolites were determined using an HPLC method with fluorescence detection. Pharmacokinetic variables were determined using non-compartmental methods. Neuromuscular block was assessed by measuring the electromyographic evoked response of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve using a Puritan-Bennett Datex (Helsinki, Finland) monitor. Pharmacodynamic modelling was completed using semi- parametric effect-compartment analysis. Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns). The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns). The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns). After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively. In summary, minor differences in the pharmacokinetics and pharmacodynamics of cisatracurium in liver transplant and control patients were not associated with any clinically significant differences in recovery profiles after a single dose of cisatracurium.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
A. Richard, F. Girard, D. C. Girard, D. Boudreault, P. Chouinard, R. Moumdjian, A. Bouthilier, M. Ruel, J. Couture, and F. Varin
Cisatracurium-Induced Neuromuscular Blockade Is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients
Anesth. Analg., February 1, 2005; 100(2): 538 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
E. W. Moore and J. M. Hunter
The new neuromuscular blocking agents: do they offer any advantages?
Br. J. Anaesth., December 1, 2001; 87(6): 912 - 925.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. Vuylsteke, Q. Milner, H. Ericsson, D. Mur, J. Dunning, A. Jolin-Mellgard, M. Nordlander, and R. Latimer
Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass{dagger}
Br. J. Anaesth., November 1, 2000; 85(5): 683 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
W. S. Jellish, M. Brody, K. Sawicki, and S. Slogoff
Recovery from Neuromuscular Blockade After Either Bolus and Prolonged Infusions of Cisatracurium or Rocuronium Using Either Isoflurane or Propofol-Based Anesthetics
Anesth. Analg., October 1, 2000; 91(5): 1250 - 1255.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.